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This study was to investigate the anti-obesity effects of 
diglyceride (DG)-conjugated linoleic acid (CLA) containing 
22%  CLA  as  fatty  acids  in  C57BL/6J  ob/ob  male  mice. 
There  were  four  experimental  groups  including  vehicle 
control, DG, CLA, and DG-CLA. The test solutions of 750 
mg/kg dose were orally administered to the mice everyday 
for 5 weeks. CLA treatments significantly decreased mean 
body weight in the obese mice throughout the experimental 
period  compared  to  the  control  (p  ＜  0.01).  All  test 
solutions significantly decreased the levels of triglyceride, 
glucose and free fatty acids in the serum compared with 
control (p ＜ 0.05). The levels of total cholesterol were also 
significantly  reduced  in  DG  and  DG-CLA  groups 
compared  with  the  control  group  (p  ＜  0.05).  CLA 
significantly  decreased  weights  of  renal  and  epididymal 
fats compared with the control (p ＜ 0.05). DG and DG- 
CLA  also  significantly  decreased  the  epididymal  fat 
weights compared with the control (p ＜ 0.05). A remarkable 
decrease in the number of lipid droplets and fat globules 
was observed in the livers of mice treated with DG, CLA, 
and DG-CLA compared to control. Treatments of DG and 
CLA  actually  increased  the  expression  of  peroxisome 
proliferator-activated  receptor  gamma.  These  results 
suggest  that  DG-CLA  containing  22%  CLA  have  a 
respectable anti-obesity effect by controlling serum lipids 
and fat metabolism. 
Keywords: conjugated linoleic acid, C57BL/6J ob/ob mouse, 
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Introduction 
Obesity is a major public health problem and main cause 
of most of geriatric diseases in Western countries. It is 
associated with many health risks, including heart disease, 
diabetes mellitus, stroke, high blood pressure, gallbladder 
disease, and some forms of cancer [17,26]. According to a 
recent report from the National Health and Nutrition 
Examination Survey in the United States, it was estimated 
that over 65% of adults were overweight or obese, and 16% 
of children were overweight [13,31]. Although diet, 
especially dietary fat, has been recognized as contributing 
to the development of obesity, differential effects have 
arisen with respect to individual fatty acids [15,17].
The physiological and anti-obesity effects of diglyceride 
(DG), which consists mainly of 1,3-DG, have been 
reported in numerous studies [27,38]. A single dose of DG 
emulsion lowers the extent of increase in postprandial 
serum triglyceride (TG) levels in rats [38]. Dietary DG, in 
contrast to TG, decreases both body weight and visceral fat 
mass as determined by computed tomography in healthy 
men [29]. In addition, dietary DG suppresses the accumulation 
of high-fat and high-sucrose diet-induced body fat in 
C57BL/6J mice [28]. 
Conjugated linoleic acid (CLA) refers to a group of 
isomers of linoleic acid (cis-9, cis-12 octadecadienoic 
acid). These isomers can either be positional (shifting of 
double bonds to 9∼11 or 10∼12 positions), geometric 
(cis/trans variations), or a combination of both. The major 
dietary source of CLA for humans is ruminant meats such 
as beef and lamb, and diary products including milk and 
cheese [10,22,34]. CLA has been reported to be 
anticarcinogenic [10,34], antiatherogenic [19], and 
immunomodulating agents [37]. More recently, a crude 
mixture of CLA isomers has been shown to reduce body fat 
and enhance fat-free mass in animals and humans [2,33]. In 190    Jin-Joo Hue et al.
Table 1. The composition of fatty acids in test compounds used in
this study 
Amounts of fatty acids (%)
PA SA OA  LA CLA LLA  Others
DG 3 3  31  56  򰠏  4 4 
CLA  6  3  12    2  74  2  1 
DG-CLA 3  2  24 43  22  3  3 
The composition of fatty acids was analyzed by gas chromato-
graphy. DG: diglyceride, PA: palmitic acid, SA: stearic acid, OA:
oleic acid, LA: linoleic acid, CLA: conjugated linoleic acid, 
LLA: linolenic acid. 
addition, the treatment of CLA during adipocyte 
differentiation reduces lipid accumulation and inhibits the 
expression of peroxisome proliferator-activated receptor 
gamma (PPAR-γ), which is a nuclear receptor that activates 
genes involved in lipid storage and metabolism [4,14].
PPAR-γ is expressed at the highest level in adipose tissue 
[9], colon epithelium [21], and macrophages [25]. In 
contrast to these tissues or cells, the expression of PPAR-γ 
in the liver is very low [12] and the function of PPAR-γ in 
the liver is unclear. However, it is noteworthy that PPAR-γ 
is expressed at elevated levels in the liver of a number of 
murine models of diabetes or obesity, including acid 
binding protein (aP2)/DTA [7], A-ZIP/F1 [8], ob/ob [23], 
db/db [23], and KKA [3], mutant mice. Levels of hepatic 
PPAR-γ are elevated by seven- to nine-fold in ob/ob and 
db/db mice compared with wild-type mice [23].
DG and CLA have been reported to have anti-obesity 
effects in humans and animals [19,28,29,33]. In the present 
study, DG-CLA may have a synergistic effect on 
anti-obesity compared to DG or CLA alone. Here, we 
investigated the effects of DG, CLA, and DG-CLA on 
anti-obesity in an animal model of C57BL/6J ob/ob mice 
as determined with body weight, serum lipid levels, 




Experimental materials including DG, CLA, and DG- 
CLA were obtained from the Illshinwells (Korea). CLA 
typically produced for experimental purposes was 
composed of the cis-9,trans-11 and trans-10,cis-12 isomers 
(approximately a 50 : 50 ratio). The composition of fatty 
acids of DG, CLA, and DG-CLA was analyzed by gas- 
liquid chromatography (Table 1). DG-CLA was produced 
according to patent No. 10-0540875 (Illshinwells, Korea). 
Experimental Animals 
Five week-old C57BL/6J ob/ob male mice were obtained 
from Japan SLC (Japan). The animal room was maintained 
as follows; a 12-h light/dark cycle, 10-times room air 
changes per h, 21∼24
oC temperature and 35∼65% 
relative humidity. Animal experiments were performed in 
accordance with Standard Operation Procedures of 
Laboratory Animals that were approved by Institutional 
Animal Care and Use Committee of Laboratory Animal 
Research Center at Chungbuk National University. 
Experimental design 
Mice weighing an average of about 47 g were divided into 
4 groups, including vehicle control, DG, CLA, and DG- 
CLA. Animals were treated orally with 10 mL/kg of 0.5% 
methyl cellulose for the control and 750 mg/kg for the three 
test solutions for the treated groups daily for 5 weeks. The 
body weight was measured twice a week and the feed and 
water intake were measured every week. After 5 weeks, 
animals were anesthetized with ether and blood samples 
were collected by a syringe from the abdominal aorta and 
immediately transferred into serum separator tubes. The 
liver was sampled for microscopical examination. 
Serum lipids and blood chemistry 
Serum was separated by centrifuging whole blood at 
3,000 rpm for 20 min. Serum lipids were analyzed using a 
blood chemistry analyzer (Hitachi, Japan). The levels of 
serum TG, total cholesterol (T-CHO), low-density lipoproteins 
(LDL), high-density lipoproteins (HDL), glucose (Glu), 
glutamic oxaloacetic transaminase (GOT), γ-glutamate- 
pyruvate transaminase (γ-GPT), blood urea nitrogen 
(BUN), and creatinine (CRE) were determined. 
Abdominal fat weight 
Abdominal fats including mesentery, renal, and epididymal 
fats were carefully separated and weighed. The relative fat 
weight (%) was calculated based on final body weight.
 Histopathology 
Mice livers were fixed in 10% neutral buffer formalin and 
embedded in paraffin. Sections of 4-μm thickness were 
stained with hematoxylin and eosin according to the 
general procedures. In addition, the livers frozen in a deep 
freezer (Revco, USA) were embedded in OCT compounds, 
and 10-μm thick sections were stained with oil red O. 
Morphology of the livers was examined under a 
light-microscope (Olympus, Japan). 
Western blot analysis 
The livers were homogenized in a lysis buffer containing 
20 mM Hepes (pH 7.5), 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 1 mM EGTA, 100 mM NaF, 10 mM sodium 
pyrophophate, and 1 mM Na3VO3. The soluble materials Anti-obesity effect of CLA-containing diglyceride in obese mice    191
Fig. 1. Change in body weights of C57BL/6J ob/ob male mice 
for 5 weeks. DG: diglyceride, CLA: conjugated linoleic acid, 
DG-CLA: DG containing 22% CLA as fatty acid. Data is 
expressed as the means ± SE (n = 10). *Significantly different 
from the control at p ＜ 0.01.
Fig. 2. Daily feed intake of C57BL/6J ob/ob mice for 5 weeks. 
Data represent the means ± SE (n = 10). *Significantly different
from the control at p ＜ 0.01.
were removed by centrifugation at 12,000 rpm for 20 min 
and protein level was determined using the Bradford 
protein assay. The lysates (50 μg of protein) were resolved 
on a sodium dodacyl sulfate-10% polyacrylamide gel and 
transferred onto PVSF membrane (Hoefer, USA). The 
blots were blocked with 5% skim milk in TNT (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl and 0.1% Tween 20) 
solution and then incubated at 4
oC overnight with either 
PPAR-γ antibody (1 : 1,000; Santa Cruz Biotechnology, 
USA) or GAPDH (1 : 1,000; Cell Signaling Technology, 
USA) diluted with 3% skim milk. The blots were then 
incubated with anti-mouse horseradish peroxidase- 
conjugated antibody (1 : 1,000; Cell Signaling Technology, 
USA) or anti-rabbit horseradish peroxidase-conjugated 
antibody (1 : 1,000; Cell Signaling Technology, USA). 
Signals were detected by using the enhanced chemilumi-
nescence method using WEST-ONE (iNtRON Biotechnology, 
Korea). 
Statistical analysis 
Data were expressed as the mean ± SE. Statistical 
significance between control group and treatment groups 
were determined by one-way ANOVA, followed by the 
LSD using the SPSS 10.0 statistic computer program. A 
difference at the level of p ＜ 0.05 or p ＜ 0.01 was 
considered to be statistically significant. 
Results
Change in body weight and feed intake 
CLA treatment significantly decreased the mean body 
weights in the obese mice throughout the experimental 
periods compared with the control (Fig. 1) (p ＜ 0.01). 
Meanwhile, treatments of DG or DG-CLA did not 
significantly decrease the mean body weight compared to 
control (Fig. 1). The decrease in body weight by CLA was 
also significantly different from the DG or DG-CLA 
groups (p  ＜  0.05). The daily feed intake for the 
experimental period in the CLA group was significantly 
lower than the control and DG groups (Fig. 2) (p ＜ 0.01). 
The reduction of body weight was strongly associated with 
the decrease in food consumption of the obese mice. 
Changes in serum lipids level and blood biochemistry 
The obese mice (C57BL/6J ob/ob) had greater levels of 
TG, T-CHO, HDL, LDL, Glu, FFA, GOT, and γ-GPT, 
compared with the respective lean mice (C57BL/6J) (data 
not shown). The DG, CLA, and DG-CLA treatments 
significantly decreased serum TG levels in the obese mice 
(Table 2, p  ＜ 0.05). DG and DG-CLA groups had a 
significant reduction T-CHO levels and a significant 
increase in serum HDL levels compared with the control 
group (Table 2, p ＜ 0.05). The levels of Glu and FFA were 
also significantly decreased by DG, CLA, and DG-CLA 
treatments (Table 2). DG-CLA had the strongest reducing 
effect on serum Glu and FFA levels among the treatments. 
CLA significantly increased serum γ-GPT and CRE levels, 
while DG-CLA significantly decreased BUN levels 
compared with the control (p ＜ 0.05). 
Relative abdominal fat weights 
Abdominal fat weights, including mesentery, renal, and 
epididymal fats were measured in relation to final body 
weight (Table 3). There were no significant differences in 
mesentery fat weight among experimental groups. CLA 
significantly decreased renal fat weight compared to 
control (p ＜ 0.05), while DG significantly increased the 
renal fat weight (Table 3). DG, CLA, and DG-CLA 
treatments caused a significant decrease in epididymal fat 
weight compared with the control (p ＜ 0.05). The abdominal 192    Jin-Joo Hue et al.
Table 2. Serum chemistry in C57BL/6J ob/ob mice
Serum parameters Control DG CLA DG-CLA
TG (mg/dL) 105.12 ± 10.63 33.38 ± 1.76*    38.44 ± 4.10* 35.64 ± 4.06*
T-CHO (mg/dL) 291.70 ± 20.18 247.04 ± 6.20* 283.04 ± 5.58 246.38 ± 7.39*
HDL (mg/dL) 72.68 ± 3.07 79.26 ± 1.38* 72.46 ± 5.64 79.86 ± 2.17*
LDL (mg/dL) 11.56 ± 1.21 13.98 ± 0.84   11.06 ± 0.84 13.60 ± 1.36
Glu (mg/dL) 790.06 ± 97.87 471.78 ± 37.38* 561.48 ± 38.17* 361.18 ± 16.78*
FFA (mEq/L) 3,534.4 ± 208.1 1,851.0 ± 309.8* 1,914.0 ± 215.4* 1,765.3 ± 145.5*
GOT (IU/L) 589.62 ± 93.38 495.56 ± 24.73 473.56 ± 31.72 534.76 ± 61.64
γ-GPT (IU/L) 572.24 ± 64.75 618.96 ± 79.74  848.60 ± 53.79* 602.76 ± 112.98
CRE (IU/L) 0.35 ± 0.03 0.46 ± 0.04 0.46 ± 0.02* 0.38 ± 0.04
BUN (IU/L) 43.36 ± 10.40 35.72 ± 1.96 39.96 ± 3.45 33.18 ± 1.23*
DG-CLA: DG containing 22% CLA as fatty acid, TG: triglyceride, T-CHO: total cholesterol, LDL: low-density lipoproteins, HDL: 
high-density lipoproteins, Glu: glucose, FFA: free fatty acid, GOT: glutamic oxaloacetic transaminase, γ-GPT: glutamate-pyruvate 
transaminase, BUN: blood urea nitrogen, CRE: creatinine. Data represent means ± SE (n = 6). *Significant different from the control group
at the level of p < 0.05.
Table 3. Relative abdominal fat weights in C57BL/6J ob/ob mice
Final body  Mesentery  Renal  Epididymal 
 Groups
weight (g) fat (%) fat (%) fat (%)
Control 56.45 ± 1.26 4.2 ± 0.1  4.8 ± 0.2 7.7 ± 0.3 
DG 54.02 ± 1.33 3.8 ± 0.1   6.6 ± 0.3*  6.5 ± 0.2*
CLA 43.91 ± 1.94 4.1 ± 0.3   4.0 ± 0.2*  5.7 ± 0.2*
DG-CLA 　54.16 ± 1.01 4.0 ± 0.1 5.5 ± 0.2  6.5 ± 0.1*
Data represents means ± SE (n = 6). *Significant different from the 
control group at the level of p < 0.05.
Fig. 3. Microphotographs of the liver of C57BL/6J ob/ob mice.
Many fat droplets were diffusely present in the liver of the obese
mice in control and treated with test solutions. (A) Control, (B) 
Diglyceride, (C) Conjugated linoleic acid, (D) Diglyceride 
containing 22% conjugated linoleic acid. H&E stain, ×200.
fat weight, as the sum of the weights of mesentery, renal, 
and epididymal fats, was only significantly decreased by 
CLA treatments. 
Histopathology in liver
Livers of the control mice (C57BL/6J ob/ob) had numerous 
lipid droplets compared with those from lean normal mice 
(C57BL/6J) (data not shown). Large fat droplets were 
present diffusely in the liver of the control obese mice (Fig. 
3). The treatment CLA and DG-CLA showed a reasonable 
decrease in the number of lipid droplets compared to the 
control (Fig. 3). In the liver stained with oil red O, a 
remarkable decrease in lipid droplets by CLA and DG- 
CLA treatments were clearly shown, compared with the 
control (Fig. 4). Treatment of DG also weakly ameliorated 
the lipid accumulation in the liver cells compared with the 
control (Fig. 4).
PPAR-γ expression 
Expression of PPAR-γ by the treatments was determined 
by western blot analysis. DG, CLA, and DG-CLA increased 
the expression of PPAR-γ compared with the control (Fig. 
5), with the expression of PPAR-γ by CLA the highest 
among the treatments (Fig. 5). 
Discussion
CLA has been approved as a functional food for 
controlling obesity in humans [33]. The objective of the 
present study was to investigate the anti-obesity effects of 
DG, CLA and DG-CLA containing 22% CLA as fatty Anti-obesity effect of CLA-containing diglyceride in obese mice    193
Fig. 4. Lipid accumulation in the liver of C57BL/6J ob/ob mice.
Many fat droplets were diffusely present in the liver of the obese
mice with control (A), while the treatments of diglyceride (B), 
conjugated linoleic acid (C), and diglyceride containing 22% 
conjugated linoleic acid (D) decreased the number of fat droplets. 
Oil red O staining, ×200.
Fig. 5. Expression of PPAR-γ in the liver of C57BL/6J ob/ob
mice. All samples in gels were equally loaded with 50 μg of total
protein and GAPDH was used as an internal control for equal 
protein loading. As compared with the control (A), the expression
of PPAR-γ increased with the treatment of diglyceride (B), 
conjugated linoleic acid (C), and diglyceride containing 22% 
conjugated linoleic acid as fatty acid (D).
acids in C57BL/6J ob/ob mice. In the present study, CLA 
decreased body weight, serum lipids levels, and abdominal 
fat mass without hepatotoxicity and nephrotoxicity. DG 
and DG- CLA also decreased the serum levels of TG, 
T-CHO, Glu, and FFA, compared with the control. The 
effects on these anti-obesity biomarkers may be derived 
from the well- known functions of DG and CLA in 
previous studies [19,28,33,39]. 
Recently, dietary CLA has been shown to reduce body fat 
mass in various experimental animals, including lean/ 
obese mice [11,24,32,35,36,41]. The C57BL/6J ob/ob 
mouse has been widely used in obesity research as a 
representative animal of obesity [21,28].  Obesity in these 
mice is result of a point mutation in the leptin gene, Lep. 
The ligand, leptin, has been shown to be a key weight 
control hormone that is mutated in the mouse obesity 
mutation [18].
To care and prevent obesity, decreases in body weight and 
body fat are important as the preferential target [11,13,41]. 
Several investigators have reported that CLA is an 
effective regulator of body fat accumulation and retention 
[35,36]. This five weeks trial using C57BL/6J ob/ob mice 
and treatment with CLA significantly decreased body 
weight in this study. The body weight of the animals was 
closely related to daily food consumption. The ob/ob or 
diet- induced obese mice receiving a recombinant form of 
ciliary neurotrophic factor exhibit preferential loss of fat 
mass and a decrease in feed consumption [18]. The 
treatment of CLA reduced the food consumption that may 
be associated with the significant weight loss in the obese 
mice in this study. The CLA inhibited abdominal fat 
weights which may be associated with their suppression of 
adipocyte differentiation and adipogenesis. Mesentery, 
renal, and epididymal fat mass in the abdomen of mice 
were significantly decreased by CLA treatment. The 
specific mechanism by which CLA exerts these effects 
remains unknown, but several hypotheses have been 
offered, including the inhibition of arachidonic acid 
formation and modulation of desaturase activity in the liver 
[20,37]. Obese mice have numerous metabolic abnorma-
lities associated with lipid metabolism including increased 
lipid accretion and reduced desaturase activity [1,5]. 
The lipid accumulation of adipocytes is determined by a 
balance of lipogenesis and lipolysis. In the present study 
CLA and DG-CLA ameliorated the lipid accumulation in 
the liver of obese mice compared with the control. DG has 
also been reported to have anti-obesity effects in numerous 
studies showing decreased body weight, visceral fat, and 
serum TG levels with treatment [28,29]. In this study, DG 
and DG-CLA decreased total cholesterol levels, and DG, 
CLA, and DG-CLA decreased serum TG levels. These 
results show that CLA and/or DG can regulate lipogenesis 
and lipolysis to maintain lipid levels in the blood of the 
obese mice. The decreased levels of serum TG, Glu, and 
FFA by test solutions might be associated with the decrease 
of food intake in this study. However, the reducing effects 
on these serum values were stronger in the DG or DG-CLA 
group than the CLA group, indicating that their effects 
were not relevant to the daily feed intake. 
The PPAR-γ, CC/AAT/enhancer binding protein α, and 
fatty aP2 are transcription factors known to be important in 
adipocyte differentiation and maturation [27]. The mechanism 
of how hepatic PPAR-γ is induced in the liver of ob/ob 
mouse remains elusive. It is known that the expression of 
hepatic PPAR-γ is increased in some obese and diabetic 
model mice [7]. In addition, the function of PPAR-γ in the 
liver is still unclear. A down-regulation of the genes might 
be correlated with the subsequent attenuation of lipid 194    Jin-Joo Hue et al.
accumulation as described above. In this study, the 
treatment of DG and CLA remarkably increased PPAR-γ 
expression compared with the control. Some workers 
reported that t10, c12-CLA, but not c9 and t11-CLA 
activates PPAR-γ [16]. In adipose tissue, CLA t10 and c12 
decreased adipogenesis by a mechanism that involves 
decreased expression of PPAR-γ [6]. In contrast, CLA 
increases both PPAR-γ mRNA expression and insulin 
sensitivity in rats [23]. In addition, prolonged treatment 
with CLA activated the expression of PPAR-γ in lepob/ 
lepob mice [40]. Therefore, activation or depression of 
PPAR-γ may differ for various conditions. In our study, DG 
and CLA actually increased PPAR-γ expression in the liver 
of the C57BL/6J ob/ob mice, but its function in the liver is 
still elusive. 
In conclusion, CLA decreased body and abdominal fat 
weights and serum lipid levels, most likely due to a loss of 
appetite and modulation of lipid metabolism in C57BL/6J 
ob/ob mice. DG and DG-CLA also decreased serum levels 
of TG, T-CHO, Glu, and FFA more strongly than CLA. 
Although DG and DG-CLA did not decrease body weight, 
they may play an important role in lipid metabolism, 
resulting in improving human health. 
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